These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 11320359)

  • 1. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels.
    Tsevat J; Kuntz KM; Orav EJ; Weinstein MC; Sacks FM; Goldman L
    Am Heart J; 2001 May; 141(5):727-34. PubMed ID: 11320359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study.
    Tonkin AM; Eckermann S; White H; Friedlander D; Glasziou P; Magnus P; Kirby A; Mulray S; Denton M; Sallaberger M; Hunt D; Simes J;
    Am Heart J; 2006 Jun; 151(6):1305-12. PubMed ID: 16781242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan.
    Nagata-Kobayashi S; Shimbo T; Matsui K; Fukui T
    Int J Cardiol; 2005 Sep; 104(2):213-23. PubMed ID: 16168816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of captopril therapy after myocardial infarction.
    Tsevat J; Duke D; Goldman L; Pfeffer MA; Lamas GA; Soukup JR; Kuntz KM; Lee TH
    J Am Coll Cardiol; 1995 Oct; 26(4):914-9. PubMed ID: 7560617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
    Sorensen SV; Frick KD; Wade A; Simko R; Burge R
    Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.
    Johannesson M; Jönsson B; Kjekshus J; Olsson AG; Pedersen TR; Wedel H
    N Engl J Med; 1997 Jan; 336(5):332-6. PubMed ID: 9011785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacoeconomic evaluation of pravastatin in coronary secondary prevention in patients with myocardial infarct or unstable angina pectoris. An analysis based on the LIPID Study].
    Szucs TD; Bertel O; Darioli R; Gutzwiller F; Mordasini R
    Praxis (Bern 1994); 2000 Apr; 89(18):745-52. PubMed ID: 10823012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
    Giraldez RR; Giugliano RP; Mohanavelu S; Murphy SA; McCabe CH; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2008 Sep; 52(11):914-20. PubMed ID: 18772061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
    Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K
    Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S; Schuster H; Barter P; Watkins C; Kallend D;
    Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
    Chan PS; Nallamothu BK; Gurm HS; Hayward RA; Vijan S
    Circulation; 2007 May; 115(18):2398-409. PubMed ID: 17452609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
    Hague W; Forder P; Simes J; Hunt D; Tonkin A;
    Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Victory in primary prevention--or? Can we afford to translate results from the West-of-Scotland Study into general practice?].
    Klose G
    Fortschr Med; 1996 Jun; 114(17):231-2. PubMed ID: 8767302
    [No Abstract]   [Full Text] [Related]  

  • 16. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
    Hirsch M; O'Donnell JC; Jones P
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):18-28. PubMed ID: 15703502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
    Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
    Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electrocardiographic events and cholesterol reduction with pravastatin in patients with hypercholesterolemia: the Hokuriku Lipid Coronary Heart Disease Study-Pravastatin Atherosclerosis Trial.
    Shimizu M; Koizumi J; Miyamoto S; Origasa H; Mabuchi H;
    Int J Cardiol; 2005 Mar; 99(3):395-401. PubMed ID: 15771919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial).
    Miller PS; Smith DG; Jones P
    Am J Cardiol; 2005 Jun; 95(11):1314-9. PubMed ID: 15904635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
    Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.